miR-21在卵巢癌中的研究进展
Research progress of miR-21 in ovarian cancer
孙格格 1李新1
作者信息
- 1. 武汉大学人民医院妇产科 湖北 武汉 430060
- 折叠
摘要
卵巢癌是致死率最高的妇科恶性肿瘤,早期症状不典型,晚期预后不可控,易复发易耐药,给临床诊疗带来巨大的负担.为提高卵巢癌的早期诊断率和寻找靶向治疗新靶点,近年来研究者们致力于探索有效的生物标志物.作为研究最为广泛的小分子核糖核酸(microRNAs.miRs)之一,miR-21被发现在卵巢癌发病早期表达上调,可作为诊断卵巢癌有效的生物标志物.同时miR-21在卵巢癌的发生发展中也发挥作用,它的高表达能够促进卵巢癌细胞的增殖、侵袭和耐药.本文就miR-21在卵巢癌中的研究进展作一总结.
Abstract
Ovarian cancer is a gynecologic malignancy with the highest mortality rate.Its lack of typical symptoms in early stages,poor prognosis for patients in late stages,and tendency to recur and develop drug resistance have created a huge burden for clinical treatment.In recent years,researchers have been exploring effective biomarkers to improve the early diagnosis rate of ovarian cancer and find new targets for targeted therapy.As one of the most widely studied microRNAs(miRs),miR-21 has been found to be upregulated in the early stage of ovarian cancer development and can be used as an effective biomarker for ovarian cancer diagnosis.Meanwhile,miR-21 also plays a role in the development of ovarian cancer,and its high expression can promote the proliferation,invasion and drug resistance of ovarian cancer cells.This article summarizes the progress of miR-21 research in ovarian cancer.
关键词
miR-21/卵巢癌/生物标志物Key words
miR-21/Ovarian Cancer/Biomarker引用本文复制引用
基金项目
国家自然科学基金资助项目(61772376)
国家自然科学基金资助项目(621722302)
出版年
2024
NETL
NSTL
万方数据